# MOTS-c

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/mots-c
Canonical HTML page: https://getbiobrief.com/entity/mots-c

## Timeline

- **2026-07-24**: PCAC Votes to Recommend Six Peptides — The committee votes to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for inclusion on the 503A Bulks List, culminating the multi-day review.
- **2026-07-23**: FDA PCAC Public Meeting Begins — The Pharmacy Compounding Advisory Committee commences a two-day meeting to review nominations of bulk drug substances, including six peptide candidates, for the 503A Bulks List.
- **2026-07**: FDA Advisory Panel Hearing — Marathon hearing votes 6-1 to back compounding of six peptide therapies, including BPC-157, TB-500, and MOTS-c, despite FDA scientists' concerns.

## Recent coverage (2 stories)

### FDA Panel Greenlights 6 of 7 Peptide Therapies, Signaling Shift in Bioregulatory Framework
2026-08-03 18:47:47 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Despite FDA scientists’ safety concerns, an advisory panel overwhelmingly backed six peptide therapies for compounding, including TB-500 and MOTS-c. The biotech sector watches closely as the FDA prepares for rulemaking, which may redefine the boundary between pharmaceutical development and pharmacy compounding.
Full story: https://getbiobrief.com/story/fdapanel-6-peptide-therapies-bioregulatory-shift

### FDA Panel OKs 6 Longevity Peptides for Compounding, Vanta Advances Biotech Strategy
2026-08-01 14:29:54 · Sentiment: Strongly positive · Impact: 6/10 · Sources: 2

An FDA advisory committee endorsed six peptide substances for the 503A Bulks List, a milestone that could validate the therapeutic potential of BPC-157, TB-500, MOTS-c and others. Vanta is leveraging this to build a biotech platform combining peptide manufacturing with its consumer health portfolio.
Full story: https://getbiobrief.com/story/fda-advisory-vote-six-peptides-bio-platform

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.